AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nektar Therapeutics Q3 Earnings Boost Analysts' Bullish Outlook
ByAinvest
Monday, Nov 10, 2025 7:56 am ET1min read
Nektar Therapeutics' Q3 results exceeded expectations, with revenues of $12m beating estimates by 16%. Statutory losses were $1.87, 28% smaller than expected. Analysts revised their forecasts, with revenues expected to be $40m in 2026, a 36% reduction from the previous year. Losses are forecast to balloon 53% to $9.70 per share. The consensus price target rose 8.7% to $105.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet